Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 3/20 | 0.59 |
| ▸ | REN | P00797 | 2/20 | 0.54 |
| ▸ | CTSK | P43235 | 3/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.54 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.54 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.53 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.53 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.52 |
| ▸ | KLK7 | P49862 | 1/20 | 0.52 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21981346 | 1.00 | CAPN1 (0.59) | CAPN1RENCTSKCTSLHTRA1 | |
| SCHEMBL20669109 | 0.97 | CTSK (0.58) | CAPN1CTSKCTSLCAPN2SIRT2 | |
| SCHEMBL21981287 | 0.97 | CTSK (0.58) | CAPN1CTSKCTSLCAPN2SIRT2 | |
| SCHEMBL18229263 | 0.95 | REN (0.60) | RENCTSKCTSLCTSS | |
| SCHEMBL20669112 | 0.95 | REN (0.60) | RENCTSKCTSLCTSS | |
| SCHEMBL21981425 | 0.94 | CAPN1 (0.58) | CAPN1RENCTSKCTSLCAPN2 | |
| SCHEMBL21981423 | 0.94 | CAPN1 (0.58) | CAPN1RENCTSKCTSLCAPN2 | |
| SCHEMBL24130639 | 0.93 | KLK7 (0.59) | CAPN1CTSKCAPN2SIRT2SIRT1 | |
| SCHEMBL24130643 | 0.93 | KLK7 (0.59) | CAPN1CTSKCAPN2SIRT2SIRT1 | |
| SCHEMBL20173867 | 0.92 | REN (0.62) | CAPN1RENCTSKCTSLCAPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109280076-B | Peptide amide compound, preparation method and medical application thereof | 四川海思科制药有限公司 | 2022-04-05 | — | — | CN | disclosed |
| EP-3656782-B1 | PEPTIDE AMIDE COMPOUND AND PREPARATION METHOD AND MEDICAL USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO LTD (CN) | 2021-12-22 | — | — | EP | disclosed |
| EP-3656782-B1 | PEPTIDE AMIDE COMPOUND AND PREPARATION METHOD AND MEDICAL USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO LTD (CN) | 2021-12-22 | — | — | EP | disclosed |
| US-11014964-B2 | Peptide amide compound and preparation method and medical use thereof | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2021-05-25 | — | — | US | disclosed |
| US-11014964-B2 | Peptide amide compound and preparation method and medical use thereof | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2021-05-25 | — | — | US | disclosed |
| US-20200172573-A1 | PEPTIDE AMIDE COMPOUND AND PREPARATION METHOD AND MEDICAL USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2020-06-04 | — | — | US | disclosed |
| US-20200172573-A1 | PEPTIDE AMIDE COMPOUND AND PREPARATION METHOD AND MEDICAL USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2020-06-04 | — | — | US | disclosed |
| EP-3656782-A1 | PEPTIDE AMIDE COMPOUND AND PREPARATION METHOD AND MEDICAL USE THEREOF | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2020-05-27 | — | — | EP | disclosed |
| EP-3656782-A1 | PEPTIDE AMIDE COMPOUND AND PREPARATION METHOD AND MEDICAL USE THEREOF | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2020-05-27 | — | — | EP | disclosed |
| CN-110637025-A | Peptide amide compound, preparation method and medical application thereof | 四川海思科制药有限公司 | 2019-12-31 | — | — | CN | disclosed |
| CN-109280076-A | Peptide amide class compound and preparation method thereof and purposes in medicine | 四川海思科制药有限公司 | 2019-01-29 | — | — | CN | disclosed |
| WO-2019015644-A1 | PEPTIDE AMIDE COMPOUND AND PREPARATION METHOD AND MEDICAL USE THEREOF | 四川海思科制药有限公司 | 2019-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172573-A1 | PEPTIDE AMIDE COMPOUND AND PREPARATION METHOD AND MEDICAL USE THEREOF | VIP, NPPA, GRPR | CAPN1 1778/4885REN 226/4885CTSK 602/4885 |
| US-11014964-B2 | Peptide amide compound and preparation method and medical use thereof | VIP, NPPA, GRPR | CAPN1 1778/4885REN 226/4885CTSK 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.